The aim of the present study was to evaluate the long-term prognostic value of the PAM50 intrinsic subtypes, and especially the ROR score, in patients with HR+/HER2− early-stage breast cancer after extended follow-up. This evidence concerns the gene ERBB2 and breast cancer.